Literature DB >> 9638277

Causal prophylactic activity of antihistaminic agents against Plasmodium yoelii nigeriensis infection in Swiss mice.

N Singh1, S K Puri.   

Abstract

The causal prophylactic activity of five tricyclic anti-histaminic agents (histamine H1-receptor antagonists) cyproheptadine, ketotifen, loratadine, azatadine and terfenadine was evaluated in an experimental murine malaria model. Sporozoite induced infections with Plasmodium yoelii nigeriensis (N-67), a strain innately resistant to choloroquine, were employed for the efficacy test and pyrimethamine and primaquine were used as standard reference drugs. Treatment with cyproheptadine or ketotifen at 5 mg/kg and terfenadine at 50 mg/kg, orally for 3 days (-1, 0, +1) completely prevented the establishment of patent infection in mice inoculated with 1 x 10(5) sporozoites on day 0. Partial activity was recorded with lower doses of the above agents as well as with azatadine and loratadine at 10 mg/kg as indicated by marginal delay in the development of patent infection after sporozoite challenge. None of these agents showed blood schizontocidal activity at doses found effective in the causal prophylactic test, though initial suppression of parasitaemia was observed with cyproheptadine and ketotifen at higher doses. This study is the first report on efficacy of antihistaminic agents for growth inhibition of pre-erythrocytic stages of any malaria parasite.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9638277     DOI: 10.1016/s0001-706x(97)00138-1

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  7 in total

Review 1.  A pre-emptive strike against malaria's stealthy hepatic forms.

Authors:  Dominique Mazier; Laurent Rénia; Georges Snounou
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

2.  Mast cells and histamine alter intestinal permeability during malaria parasite infection.

Authors:  Rashaun A Potts; Caitlin M Tiffany; Nazzy Pakpour; Kristen L Lokken; Connor R Tiffany; Kong Cheung; Renée M Tsolis; Shirley Luckhart
Journal:  Immunobiology       Date:  2015-11-25       Impact factor: 3.144

3.  Drug repositioning: antiprotozoal activity of terfenadine against Entamoeba histolytica trophozoites.

Authors:  Itzia Azucena Rangel-Castañeda; Araceli Castillo-Romero; Gloria León-Ávila; Martin Zermeño-Ruiz; José Manuel Hernández-Hernández
Journal:  Parasitol Res       Date:  2021-11-06       Impact factor: 2.289

4.  HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.

Authors:  Charlotte V Hobbs; Tatiana Voza; Alida Coppi; Brian Kirmse; Kennan Marsh; William Borkowsky; Photini Sinnis
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

5.  A plant-derived morphinan as a novel lead compound active against malaria liver stages.

Authors:  Maëlle Carraz; Akino Jossang; Jean-François Franetich; Anthony Siau; Liliane Ciceron; Laurent Hannoun; Robert Sauerwein; François Frappier; Philippe Rasoanaivo; Georges Snounou; Dominique Mazier
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

6.  Identification of a novel potassium channel (GiK) as a potential drug target in Giardia lamblia: Computational descriptions of binding sites.

Authors:  Lissethe Palomo-Ligas; Filiberto Gutiérrez-Gutiérrez; Verónica Yadira Ochoa-Maganda; Rafael Cortés-Zárate; Claudia Lisette Charles-Niño; Araceli Castillo-Romero
Journal:  PeerJ       Date:  2019-02-27       Impact factor: 2.984

Review 7.  Repurposing Drugs to Fight Hepatic Malaria Parasites.

Authors:  Diana Fontinha; Isabel Moules; Miguel Prudêncio
Journal:  Molecules       Date:  2020-07-28       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.